Estrella Immunopharma
ESLA
13 hedge funds and large institutions have $879K invested in Estrella Immunopharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
57% more capital invested
Capital invested by funds: $560K → $879K (+$319K)
18% more funds holding
Funds holding: 11 → 13 (+2)
0.25% more ownership
Funds ownership: 1.76% → 2.01% (+0.25%)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$131K |
| 2 |
Renaissance Technologies
New York
|
+$10.3K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.96K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$21.5K |
| 2 |
HF
HRT Financial
New York
|
-$14K |
| 3 |
BlackRock
New York
|
-$7.03K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.77K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$555 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $499K | +$131K | +136,868 | +48% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $121K | -$1.77K | -1,847 | -2% |
|
3
Citadel Advisors
Miami,
Florida
| $59.6K | -$33 | -34 | -0.1% |
|
|
4
UBS Group
Zurich,
Switzerland
| $57.9K | -$21.5K | -22,426 | -31% |
|
|
ASM
5
ATW SPAC Management
New York
| $46K | – | – | – |
|
|
6
BlackRock
New York
| $27.7K | -$7.03K | -7,323 | -23% |
|
7
State Street
Boston,
Massachusetts
| $26.6K | – | – | – |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| $12.3K | +$9.96K | +10,373 | New |
|
|
9
Renaissance Technologies
New York
| $12.3K | +$10.3K | +10,689 | New |
|
|
MCP
10
Maso Capital Partners
Hong Kong
| $11.5K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $4.62K | -$555 | -578 | -13% |
|
12
Bank of America
Charlotte,
North Carolina
| $2 | -$86 | -90 | -98% |
|
|
SS
13
SBI Securities
Tokyo,
Japan
| $1 | +$1 | +1 | New |
|
|
HF
14
HRT Financial
New York
| – | -$14K | -17,266 | Closed |
|
ESLA Hedge Fund Activity: Q3 2025 in Review
13 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q3 2025, worth a combined $879K — up 57% from $560K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ESLA positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $131K. The largest seller was UBS Group, cutting an estimated $21.5K.
- 13 institutional investors held Estrella Immunopharma (ESLA) as of Q3 2025, up from 11 in Q2 2025.
- Funds reported $879K of Estrella Immunopharma stock for Q3 2025, up 57% quarter-over-quarter.
- 3 funds opened new Estrella Immunopharma positions in Q3 2025 and 1 closed out, a net change of +2 holders.
- The largest Estrella Immunopharma buyer in Q3 2025 was Vanguard Group, an estimated $131K added.
- The largest Estrella Immunopharma seller in Q3 2025 was UBS Group, an estimated $21.5K sold.
Based on aggregated 13F filings for Q3 2025.